TITLE

Intranasal apomorphine: a new treatment in Parkinson's disease

AUTHOR(S)
Kapoor, R; Turjanski, N; Frankel, J; Kleedorfer, B; Lees, A; Stern, G; Bovingdon, M; Webster, R
PUB. DATE
November 1990
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Nov1990, Vol. 53 Issue 11, p1015
SOURCE TYPE
Academic Journal
DOC. TYPE
letter
ABSTRACT
No abstract available.
ACCESSION #
66067154

 

Related Articles

  • apomorphine. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p64 

    An encyclopedia entry for "apomorphine" is presented. It refers to a drug that is used to treat Parkinson's disease. Common side effects of apomorphine at the start of treatment include nausea and vomiting.

  • New molecular entities.  // Managed Healthcare Executive;Jul2004, Vol. 14 Issue 7, p54 

    Reports on the federal approval of apomorphine injection for off episodes in advanced Parkinson's disease in the U.S. Mechanism of action of the nonergoline dopamine agonist; Treatment of hypomobility.

  • New Parkinson's drug is first for acute hypomobility.  // Drug Topics;5/3/2004, Vol. 148 Issue 9, p6 

    This article reports on the approval given by the U.S. Food and Drug Administration for the use of apomorphine for the acute, intermittent treatment of hypomobility associated with advanced Parkinson's disease.

  • Apomorphine.  // Reactions Weekly;11/3/2012, Issue 1426, p11 

    The article describes the case of an elderly woman who developed multiple skin necroses and abscesses during treatment with apomorphine pump infusions for motor fluctuations in Parkinson's disease.

  • Subcutaneous apomorphine in Parkinson's disease. Chaudhuri, K Ray; Clough, C. // BMJ: British Medical Journal (International Edition);02/28/98, Vol. 316 Issue 7132, p641 

    Discusses the effectivity of continuous subcutaneous infusion of apomorphine in overcoming refractory on-off oscillations in Parkinson's disease. Motor response to apomorphine; Counselling of patients and liaison with the general practitioner; Benefits of apomorphine; Reluctance of neurologists...

  • Intermittierende Apomorphin-Injektionen als Rescue-Therapie beim fortgeschrittenen M. Parkinson. Trenkwalder, C.; Boesch, S.; Ceballos-Baumann, A.; Dressler, D.; Eggert, K.; Gasser, T.; Honig, H.; M�ller, T.; Reichmann, H.; Sieb, J.P.; Storch, A.; Odin, P.; Poewe, W. // Nervenarzt;Apr2008, Vol. 79 Issue 4, p475 

    Intermittent subcutaneous apomorphine therapy should be considered in patients with advanced Parkinson's disease who experience recurrent off periods despite optimised oral treatment (according to guidelines), for reliable and quick reversal of these otherwise refractory periods. Such treatment...

  • Apomorphine/levodopa.  // Reactions Weekly;9/19/2009, Issue 1270, p8 

    The article describes a case of psychiatric disorders induced by treatment with levodopa and apomorphine. The male patient received apomorphine and levodopa to treat his early onset Parkinson's disease. Some of the psychiatric disorders developed by the man include paraphilia and abnormal...

  • apomorphine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p160 

    The article presents a nursing guide for apomorphine, an antiparkinson agent. It is indicated for acute, intermittent treatment of hypomobility, off episodes due to advanced Parkinson's disease. The mechanism of action and pharmacokinetics are discussed. Information is presented on adverse...

  • Apomorphine.  // Reactions Weekly;3/19/2005, Issue 1043, p7 

    Discusses a case report of a woman who developed panniculitis and eosinophilia during treatment with apomorphine for Parkinson's disease. Reference to a study by C. Pot et al, published in the January 25, 2005 issue of "Neurology"; Dosage of apomorphine received by the patient; Effect of oral...

  • Apomorphine-Subcutaneous – Bertek/Britannia. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 4, p211 

    Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories Inc., is developing an intermittent subcutaneous formulation of apomorphine hydrochloride as a treatment for Parkinson's disease. Apomorphine injection (APO-go®) for the treatment of Parkinson's disease was launched in the UK in May...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics